Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InVivo names new CEO

This article was originally published in Clinica

Executive Summary

Cambridge, Massachusetts-based InVivo Therapeutics has named Mark Perrin chief executive officer – effective 6 January 2014. Upon his appointment, Mr Perrin will also become a member of the company's board of directors. Prior to joining the company – which specializes in drug delivery technologies for spinal cord injuries – Mr Perrin was president of Dennan Consulting, a biotech consulting firm. Mr Perrin replaces interim CEO Michael Astrue, who has been filling in since previous leader Francis Reynold stepped down in August due to a medical condition. Meanwhile, InVivo has also promoted Lisa Crockett to vice-president, regulatory and Kristin Neff to vice-president, clinical operations, effective 1 January 2014. The firm also recently made Steven McAllister interim CEO, making him the third person to head up its finance division in the last three months. InVivo saw its share price plunge in August after delaying its first-in-human trials of its biopolymer scaffold.

You may also be interested in...



Six New Molecules By 2030 – J&J’s Neuroscience Strategy

Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions. 

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

In Vivo's 2024 Rising Leaders At A Glance

Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT101209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel